This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
How you reward KeyAccountManagers is seen as a critical ingredient in the overall success of any KeyAccountManagement KAM strategy. The role of a keyaccountmanager requires effective coordination of a web of complex activities. Reward schemes fall into three categories: .
How you reward KeyAccountManagers is seen as a critical ingredient in the overall success of any KeyAccountManagement KAM strategy. The role of a keyaccountmanager requires effective coordination of a web of complex activities. . Reward schemes fall into three categories: 1.
Over the past decade, macro trends in healthcare have pushed life sciences companies to pursue increasingly sophisticated keyaccountmanagement (KAM) strategies and capabilities to provide unique offerings and value. How should leading pharma companies respond? Pharma Responds with Increasingly Complex KAM Strategies.
In this case, what is the issue for Pharma? Customer-facing account teams still try to develop business with a product-focused mentality at the same time that healthcare stakeholders wrestle with challenges; the timing and context of which, render product-centric approaches a distraction. . – Patient empowerment.
In this case, what is the issue for Pharma? Customer-facing account teams still try to develop business with a product-focused mentality at the same time that healthcare stakeholders wrestle with challenges; the timing and context of which, render product-centric approaches a distraction. – Patient empowerment.
Traditionally the pharma industry relied on the volume of prescriptions made. A primary challenge for pharma and bio-tech companies is how to identify the right stakeholders in the approval process. Pharma and bio-tech companies need to adopt more innovative market access tactics to succeed.
Traditionally the pharma industry relied on the volume of prescriptions made. the evolving healthcare industry, pharma and bio-tech companies are now focusing on each component of market access: – Price. A primary challenge for pharma and bio-tech companies is how to identify the right stakeholders in the approval process.
The Nationwide Pharma Marketing Excellence Awards 2022 are designed to recognize individuals who have contributed to developing innovative pharmaceutical products and services that may aid in providing patients with top-notch healthcare. Nationwide Pharma Marketing Excellence Awards-Winners list for 2022.
This will help to maximise on cross-selling opportunities, providing a seamless and customer-centric experience to Velocity’s pharma and CRO partners. She has 20 years’ experience in business development and keyaccountmanagement in the clinical trials arena.
Here, I’ll examine some common elements that I consider essential in today’s medical sales for the pharma or medical device business. As in many other businesses very often 80% of the sales come from 20% of the customers. Keyaccountmanagement Strictly related to the previous point comes the keyaccountmanagement philosophy.
A global head of sales at a pharma company recently told me that “only 15% of our sales calls end in a positive outcome.”. Why is success in pharma sales so hard? Pharma has always been highly restrictive in terms of the different tools you can use to engage, educate and inform about prescription medicines.
Companies that adopt this blended model will be able to recognise performance gaps earlier and, for the first time, align incentives across the entire commercial ecosystem, including sales reps, keyaccountmanagers, and medical science liaisons.”. Content automation will deliver as AI fails to live up to the hype.
I’ve worked in the pharmaceutical industry full-time for 24 years across a variety of roles but mostly within Leadership and Market Access, and latterly heading up KeyAccountManagement at Boehringer-Ingelheim. Our pharma partners see this as one of the most valuable assets we have to offer.
It’s important to: Consider looking at other roles that are not direct sales positions such as keyaccountmanagers, reimbursement specialists, and contact center support teams. Examine opportunities to shift resources to these areas providing greater impact in a remote environment.
Imagine what a pharma rep will look like in 10 years. We’re tailoring the user interfaces by building business apps designed for each commercial persona, such as the sales rep, field medical, keyaccountmanagement, the pharmacy rep, the event coordinator, and so on. Will they still be out driving all the time?
Number one is if you want to make the transition from pharma to medical device, many people have gone back and forth. You’ve been in both pharma and med device. We all know what they do. They all may do it a little bit differently. That comes down to messaging. What I would say is a couple of things. It can be done.
According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. The demand for injectable drugs is rising. This was higher than the number of approvals in 2019 and 2020.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content